Correlation Between Lyra Therapeutics and CytomX Therapeutics

Can any of the company-specific risk be diversified away by investing in both Lyra Therapeutics and CytomX Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyra Therapeutics and CytomX Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lyra Therapeutics and CytomX Therapeutics, you can compare the effects of market volatilities on Lyra Therapeutics and CytomX Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyra Therapeutics with a short position of CytomX Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyra Therapeutics and CytomX Therapeutics.

Diversification Opportunities for Lyra Therapeutics and CytomX Therapeutics

0.03

Correlation Coefficient

Lyra Therapeutics  CytomX Therapeutics

Significant diversification

The 3 months correlation between Lyra and CytomX is 0.03. Overlapping area represents the amount of risk that can be diversified away by holding Lyra Therapeutics and CytomX Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CytomX Therapeutics and Lyra Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyra Therapeutics are associated (or correlated) with CytomX Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CytomX Therapeutics has no effect on the direction of Lyra Therapeutics i.e., Lyra Therapeutics and CytomX Therapeutics go up and down completely randomly.

Pair Corralation between Lyra Therapeutics and CytomX Therapeutics

Given the investment horizon of 90 days Lyra Therapeutics is expected to generate 0.21 times more return on investment than CytomX Therapeutics. However, Lyra Therapeutics is 4.83 times less risky than CytomX Therapeutics. It trades about -0.4 of its potential returns per unit of risk. CytomX Therapeutics is currently generating about -0.3 per unit of risk. If you would invest  39.00  in Lyra Therapeutics on March 9, 2024 and sell it today you would lose (7.32) from holding Lyra Therapeutics or give up 18.77% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Lyra Therapeutics  vs.  CytomX Therapeutics

Lyra Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in July 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

CytomX Therapeutics

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in CytomX Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating primary indicators, CytomX Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Lyra Therapeutics and CytomX Therapeutics

The main advantage of trading using opposite Lyra Therapeutics and CytomX Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyra Therapeutics position performs unexpectedly, CytomX Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will offset losses from the drop in CytomX Therapeutics' long position.

The idea behind Lyra Therapeutics and CytomX Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.